Skip to content
Nurexone Biologic Inc episode artwork

Jul 7, 2025 12 min

Nurexone Biologic Inc

from OTCQB Podcast Hosted by OTC Markets Group

Nurexone Biologic Inc (OTCQB: NRXBF) is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Lior Shaltiel, CEO of Nurexone Biologic, joins us today to share and explain Nurexone's innovative and promising research on its lead candidate, XOP10. View Podcast Transcript

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Nurexone Biologic Inc

0:00 12:35

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OTCQB Podcast?

This episode is 12 minutes long.

When was this OTCQB Podcast episode published?

This episode was published on July 7, 2025.

Can I download this OTCQB Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.